Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia (Q86003715)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Hiroshi Mabuchi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Atsushi Nohara

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

18 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

8-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2014.205

22 February 2020

exact match

0 references

cites work

Mechanisms of disease: genetic causes of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

Lowering Plasma Cholesterol by Raising LDL Receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.205

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2014.205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25404016%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference